Shim Soon-Sup, Lee Cha Hee, Jun Jong Kwan
Department of Obstetrics and Gynecology, Jeju National University School of Medicine, Jeju, Korea.
Department of Obstetrics and Gynecology, Seoul National University College of Medicine, Seoul, Korea.
Obstet Gynecol Sci. 2015 Jan;58(1):10-6. doi: 10.5468/ogs.2015.58.1.10. Epub 2015 Jan 16.
The aim of this study was to compare midtrimester maternal plasma concentrations of angiopoietin 1, angiopoietin 2, and placental growth factor between pregnant women who subsequently developed preeclampsia and those who did not.
Midtrimester maternal plasma was collected and stored at -70℃ when genetic amniocentesis was performed. Cases included 37 samples of individual who subsequently developed preeclampsia, and matched controls were from individuals who did not develop preeclampsia. Angiopoietin 1, angiopoietin 2, and placental growth factor concentrations were measured by the enzyme-linked immunosorbent assay method and were compared using the Mann-Whitney U-test. A P-value <0.05 was considered significant.
In pregnant women who subsequently developed preeclampsia, midtrimester maternal plasma concentrations of angiopoietin 1 and angiopoietin 2 were significantly higher and placental growth factor concentrations were significantly lower than in women who did not develop preeclampsia (angiopoietin 1: 10.6 [3.1-19.7] vs. 7.8 [0.9-24.4] ng/mL, P=0.031; angiopoietin 2: 31.0 [4.7-81.2] vs. 18.4 [4.2-49.7] ng/mL, P<0.001; placental growth factor: 87.1 [14.2-774.3] vs. 148.8 [57.2-425.6] pg/mL, P<0.001). Within the case group who subsequently developed preeclampsia, the placental growth factor was significantly lower in those who had fetal growth restrictions than in those who did not (placental growth factor: 72.5 [14.2-774.3] vs. 140.9 [44.2-257.5] pg/mL, P=0.003).
Midtrimester maternal plasma concentrations of angiopoietin 1, angiopoietin 2, and placental growth factor may be associated with the subsequent development of preeclampsia.
本研究旨在比较孕中期先兆子痫孕妇与未患先兆子痫孕妇血浆中血管生成素1、血管生成素2和胎盘生长因子的浓度。
在进行遗传羊膜穿刺术时收集孕中期孕妇血浆并储存于-70℃。病例组包括37例随后发生先兆子痫个体的样本，匹配对照组来自未发生先兆子痫的个体。采用酶联免疫吸附测定法测量血管生成素1、血管生成素2和胎盘生长因子的浓度，并使用曼-惠特尼U检验进行比较。P值<0.05被认为具有统计学意义。
随后发生先兆子痫的孕妇，孕中期血浆中血管生成素1和血管生成素2的浓度显著高于未发生先兆子痫的孕妇，而胎盘生长因子浓度显著低于未发生先兆子痫的孕妇（血管生成素1：10.6[3.1 - 19.7] vs. 7.8[0.9 - 24.4] ng/mL，P = 0.031；血管生成素2：31.0[4.7 - 81.2] vs. 18.4[4.2 - 49.7] ng/mL，P<0.001；胎盘生长因子：87.1[14.2 - 774.3] vs. 148.8[57.2 - 425.6] pg/mL，P<0.001）。在随后发生先兆子痫的病例组中，有胎儿生长受限的孕妇胎盘生长因子显著低于无胎儿生长受限的孕妇（胎盘生长因子：72.5[14.2 - 774.3] vs. 140.9[44.2 - 257.5] pg/mL，P = 0.003）。
孕中期孕妇血浆中血管生成素1、血管生成素2和胎盘生长因子的浓度可能与随后先兆子痫的发生有关。
Zotero 插件